Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Genetic Association of Diabetic Retinopathy-1 (DMR-1)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2011 by Taipei Veterans General Hospital, Taiwan.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Yen Tjing Ling Medical Foundation
Information provided by (Responsible Party):
vghtpe user, Taipei Veterans General Hospital,Taiwan
ClinicalTrials.gov Identifier:
NCT01298245
First received: February 15, 2011
Last updated: December 5, 2011
Last verified: December 2011

February 15, 2011
December 5, 2011
February 2011
July 2012   (final data collection date for primary outcome measure)
The differences in the distribution of candidate genotypes and alleles between the study groups [ Time Frame: 12 months ] [ Designated as safety issue: No ]
Patients with diabetes who have received ophthalmic fundus examination within 6 months before the study. The eligible participants will be grouped by the results of prior fundus examination: those with known history of diabetic retinopathy; those without known history of diabetic retinopathy.
Same as current
Complete list of historical versions of study NCT01298245 on ClinicalTrials.gov Archive Site
the frequencies of haplotypes of different single nucleotide polymorphisms [ Time Frame: 12 months ] [ Designated as safety issue: No ]
We will estimate the frequencies of haplotypes of different single nucleotide polymorphisms, calculate linkage disequilibrium between single nucleotide polymorphisms, and conduct haplotype analysis.
Same as current
Not Provided
Not Provided
 
Genetic Association of Diabetic Retinopathy-1
Genetic Association Studies of Diabetic Retinopathy (1): Vanguard Phase

The primary purpose of the study is to investigate allele frequencies of candidate genes in Chinese diabetic patients with or without known diabetic retinopathy. Two hundred Chinese diabetic patients, aged between 20 - 75 years old, who have received ophthalmic fundus examination (either by an ophthalmoscope or fundus camera) within 6 months before the study will be recruited for the study. Each subject will receive anthropometric and blood pressure measurements. Then, fasting blood samples will be taken for the measurements of glucose, HbA1c, lipid profile, and biochemistry. An additional 10 ml blood sample will be taken for DNA extraction from buffy coat. Meanwhile, the participant will receive structural questionnaires for demography, personal history, medical history and concomitant medication. Single nucleotide polymorphisms (SNPs) in candidate genes and in targeted chromosome regions will be genotyped by using the ABI TaqMan assays. The differences in the distribution of genotypes and alleles between the study groups will be analyzed using appropriate statistical methods. Through the study, the investigators hope to build up a platform for future large-scale genetic studies of diabetic retinopathy. The investigators also hope to set up priority of candidate loci for future studies.

Diabetic retinopathy (DR) is one of the most frequent microvascular complications of diabetes (DM). Current guidelines recommend that patients with DM should receive ophthalmic fundus examination annually. DR poses a serious threat to the health of millions patients who have DM. Nowadays, DR has become the leading cause of new cases of visual impairment and blindness among adults.

Genetic factors are likely to account for the susceptibility to DR for the differences in DR incidence between individuals with diabetes. Familial aggregation studies showed that increased risk of severe DR was noted among family members with diabetes with moderate heritability of DR risk. Racial and ethnic differences in the prevalence of DR may also explain some parts of influence of genetic or environmental/cultural risk factors. There were over 30 candidate genes involved in metabolic mechanisms and functional pathways associated with DR. However, consistent associations between candidate genes and DR have yet been identified. The current study is designed to build up a working platform for future large-scale genetic studies of diabetic retinopathy. The investigators also hope to set up priority of candidate loci for future researches.

In the present study, the investigators plan to recruit 200 Chinese patients with DM who have received ophthalmic fundus examination (either by an ophthalmoscope or fundus camera) within 6 months before the study. Each subject will receive anthropometric and blood pressure measurements. Then, fasting blood samples will be taken for the measurements of glucose, HbA1c, lipid profile, and biochemistry. An additional 10 ml blood sample will be taken for DNA extraction from buffy coat. Single nucleotide polymorphisms (SNPs) in candidate genes and in targeted chromosome regions will be genotyped by using the ABI TaqMan assays. The differences in the distribution of genotypes and alleles between the study groups will be analyzed using appropriate statistical methods.

Observational
Observational Model: Case Control
Time Perspective: Cross-Sectional
Not Provided
Retention:   Samples With DNA
Description:

The participants will receive fasting blood sampling for the measurements of glucose, HbA1c, lipid profile, and biochemistry. An additional 10 ml blood sample will be taken for DNA extraction from buffy coat. Early morning urine samples will also be collected for evaluation of overt proteinuria by a dipstick method.

Non-Probability Sample

Patients with DM who have received ophthalmic fundus examination within 6 months before the study, either with or without diabetic retinopathy

  • Diabetes
  • Diabetic Retinopathy
Not Provided
  • Case: diabetic retinopathy
    Patients with diabetes who have received ophthalmic fundus examination within 6 months before the study and those with known positive results of diabetic retinopathy
  • Control: no diabetic retinopathy
    Patients with diabetes who have received ophthalmic fundus examination within 6 months before the study and those without known positive results of diabetic retinopathy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
200
December 2012
July 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with DM, diagnosed by the 2010 American Diabetes Association diagnosis criteria.
  • Men or women.
  • Aged 20 ~ 75 years old (inclusive).
  • Who have received ophthalmic fundus examination within 6 months before the study: either (1)by an ophthalmoscope or fundus camera (results reviewed by a qualified physician), or (2)the ophthalmoscopic examination being performed by an ophthalmologist.
  • Willing to participate in the study by signing an informed consent.

Exclusion Criteria:

  • Women in pregnancy.
  • No document to verify the results of the ophthalmic fundus examination requiring for the inclusion.
  • History of mental incapacity or language barriers that may preclude adequate understanding or cooperation in the study.
  • Current or concomitant illness that would interfere with the subject's ability to perform the study or that would confound the study results, judged by the investigation physicians.
Both
20 Years to 75 Years
No
Contact: Chii-Min Hwu, MD 886228757516 chhwu@vghtpe.gov.tw
Taiwan
 
NCT01298245
201008023GB, CI-99-1
No
vghtpe user, Taipei Veterans General Hospital,Taiwan
Taipei Veterans General Hospital, Taiwan
Yen Tjing Ling Medical Foundation
Principal Investigator: Chii-Min Hwu, MD Taipei Veterans General Hospital, Taiwan
Taipei Veterans General Hospital, Taiwan
December 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP